排序方式: 共有32条查询结果,搜索用时 31 毫秒
21.
目的探讨化疗联合放疗治疗局限期小细胞肺癌(SCLC)的疗效。方法将89例符合条件的局限期SCLC患者随机分为化放交替组和化放序贯组。所有患者均行EP方案化疗:顺铂40mg/d,第1~3天静脉滴注;依托泊昔100mg/d,第1—5天静脉滴注,3周为1个周期,共化疗4~6个周期。放疗常规分割,DT56~60Cy。结果交替组与序贯组完全缓解(CR)率、部分缓解率、有效率分别为38%、51%、89%和23%、61%、84%(P〉0.05);局部复发率和远处转移率分别为18%、23%和21%、30%(P〉0.05),1、2、3年生存率两组分别为71%、38%、17%和67%、31%、15%(P〉0.05)。两组Ⅱ+Ⅲa病例的CR率、2年生存率分别为65%和33%、52%和39%(P〈0.05)。结论化疗联合放疗治疗局限期SCLC近期效果满意,化放交替组和化放序贯组疗效差异无统计学意义,但TNM分期可能为影响预后的因子。 相似文献
22.
23.
Objective To evaluate efficiency of brain metastases tumor using X-knife under farctionational stereotactie radiotherapy (FSRT) combine with whole brain radiotherapy (WBRT). Methods Retrospective comparing 51 patients treated by FSRT plus WBRT (FSRT + WBRT group) with 35 patients treated by WBRT alone (WBRT group) on the effecting rate and survival rate. Results The completeness response rate was 49 % and 26 % (P < 0.05) in FSRT + WBRT and WBRT groups, respectively. The effecting rate was 80 % and 71 % (P 0.05) in FSRT + WBRT and WBRT groups, respectively. The middle survival time was (11.0 ± 1.5) months and (6.5 ± 0.5) months (P < 0.05) in FSRT + WBRT and WBRT groups, respeetivley. The 0.5-, 1.0- and 1.5-years survival rate was 63 % and 41 % (P 0.05), 51 % and 23 % (P 0.05) and 24 % and 9 % (P < 0.05) in FSRT + WBRT and WBRT groups, respectively. Conclusions The method with FSRT plus WBRT in the treatment of brain metastases tumor is safe and relieved focal symptom of patients quickly with lesser injury on normal tissue and the survival time be prolonged, it has better therapeutic effects than WBRT alone for treating brain metastases tumor. 相似文献
24.
骨骼是仅次于肺和肝的恶性肿瘤高发转移部位,随着肿瘤治疗手段的增多及治疗水平的提高,肿瘤患者的生存时间得以延长,因此,转移性骨肿瘤发生率有所增加。我们回顾总结2005年11月—2010年12月89SrCl2分别与99Tc-MDP(云克)和放疗联合治疗多发骨转移癌患者62例,现报告如下。 相似文献
25.
Objective To evaluate efficiency of brain metastases tumor using X-knife under farctionational stereotactie radiotherapy (FSRT) combine with whole brain radiotherapy (WBRT). Methods Retrospective comparing 51 patients treated by FSRT plus WBRT (FSRT + WBRT group) with 35 patients treated by WBRT alone (WBRT group) on the effecting rate and survival rate. Results The completeness response rate was 49 % and 26 % (P < 0.05) in FSRT + WBRT and WBRT groups, respectively. The effecting rate was 80 % and 71 % (P 0.05) in FSRT + WBRT and WBRT groups, respectively. The middle survival time was (11.0 ± 1.5) months and (6.5 ± 0.5) months (P < 0.05) in FSRT + WBRT and WBRT groups, respeetivley. The 0.5-, 1.0- and 1.5-years survival rate was 63 % and 41 % (P 0.05), 51 % and 23 % (P 0.05) and 24 % and 9 % (P < 0.05) in FSRT + WBRT and WBRT groups, respectively. Conclusions The method with FSRT plus WBRT in the treatment of brain metastases tumor is safe and relieved focal symptom of patients quickly with lesser injury on normal tissue and the survival time be prolonged, it has better therapeutic effects than WBRT alone for treating brain metastases tumor. 相似文献
26.
Objective To evaluate efficiency of brain metastases tumor using X-knife under farctionational stereotactie radiotherapy (FSRT) combine with whole brain radiotherapy (WBRT). Methods Retrospective comparing 51 patients treated by FSRT plus WBRT (FSRT + WBRT group) with 35 patients treated by WBRT alone (WBRT group) on the effecting rate and survival rate. Results The completeness response rate was 49 % and 26 % (P < 0.05) in FSRT + WBRT and WBRT groups, respectively. The effecting rate was 80 % and 71 % (P 0.05) in FSRT + WBRT and WBRT groups, respectively. The middle survival time was (11.0 ± 1.5) months and (6.5 ± 0.5) months (P < 0.05) in FSRT + WBRT and WBRT groups, respeetivley. The 0.5-, 1.0- and 1.5-years survival rate was 63 % and 41 % (P 0.05), 51 % and 23 % (P 0.05) and 24 % and 9 % (P < 0.05) in FSRT + WBRT and WBRT groups, respectively. Conclusions The method with FSRT plus WBRT in the treatment of brain metastases tumor is safe and relieved focal symptom of patients quickly with lesser injury on normal tissue and the survival time be prolonged, it has better therapeutic effects than WBRT alone for treating brain metastases tumor. 相似文献
27.
目的探讨^99mTc-MIBI SPECT肺肿瘤显像联合肿瘤标志物检测在老年肺肿瘤诊断中的价值。方法用^99mTc-MIBI对18例临床诊断为肺肿瘤的病人进行SPECT显像,同时对其血清癌胚抗原(CEA)、非小细胞肺癌相关抗原(CYFRA21-1)、神经元特异性烯醇化酶(NSE)肿瘤标志物利用罗氏电化学发光免疫系统进行检测。结果^99mTc-MI-BI SPECT肺肿瘤显像联合CT、MRI诊断老年肺肿瘤与病理检测符合率为94.4%,^99mTc-MIBI SPECT肺肿瘤显像联合肿瘤标志物检测诊断老年肺肿瘤与病理检测符合率为100%。结论^99mTc-MIBI SPECT肺肿瘤显像联合肿瘤标志物检测在老年肺肿瘤诊断中具有重要临床价值。 相似文献
28.
目的:观察中药丹参酮ⅡA注射液治疗老年放射性肺炎的临床疗效。方法:93例老年放射性肺炎患者,随机分为治疗组(48例)和对照组(45例)。治疗组应用丹参酮ⅡA注射液40-50mg5%GS250ml,静脉滴注,1次,日,应用20-40天。对照组应用激素和/或抗生素。结果:治疗组:显效14例(29.2%),有效32例(66.7%),无效2例(4.1%),总有效率(显效+有效)95.9%(36/48)。对照组:显效7例(15.6%),有效23例(51.1%),无效15例(33.3%),总有效率(显效+有效)66.7%(30/45)总有效率比较统计学有显著性差异(X^2=13、23,P〈0.01)。KPS升高10分以上者治疗组44例(91.7%)、对照组23例(51.1%),两组比较统计学有显著性差异(X^2=18.97,P〈0.01).复发或转移治疗组10例(20.8%)、对照组20例(44.4%),两组比较统计学有差异性(X^2=5.93,P〈0.05)。结论:丹参酮ⅡA对老年放射性肺炎具有较好的临床疗效,且安全有效,具有较好的临床应用前景。 相似文献
29.
Objective To evaluate efficiency of brain metastases tumor using X-knife under farctionational stereotactie radiotherapy (FSRT) combine with whole brain radiotherapy (WBRT). Methods Retrospective comparing 51 patients treated by FSRT plus WBRT (FSRT + WBRT group) with 35 patients treated by WBRT alone (WBRT group) on the effecting rate and survival rate. Results The completeness response rate was 49 % and 26 % (P < 0.05) in FSRT + WBRT and WBRT groups, respectively. The effecting rate was 80 % and 71 % (P 0.05) in FSRT + WBRT and WBRT groups, respectively. The middle survival time was (11.0 ± 1.5) months and (6.5 ± 0.5) months (P < 0.05) in FSRT + WBRT and WBRT groups, respeetivley. The 0.5-, 1.0- and 1.5-years survival rate was 63 % and 41 % (P 0.05), 51 % and 23 % (P 0.05) and 24 % and 9 % (P < 0.05) in FSRT + WBRT and WBRT groups, respectively. Conclusions The method with FSRT plus WBRT in the treatment of brain metastases tumor is safe and relieved focal symptom of patients quickly with lesser injury on normal tissue and the survival time be prolonged, it has better therapeutic effects than WBRT alone for treating brain metastases tumor. 相似文献
30.
Objective To evaluate efficiency of brain metastases tumor using X-knife under farctionational stereotactie radiotherapy (FSRT) combine with whole brain radiotherapy (WBRT). Methods Retrospective comparing 51 patients treated by FSRT plus WBRT (FSRT + WBRT group) with 35 patients treated by WBRT alone (WBRT group) on the effecting rate and survival rate. Results The completeness response rate was 49 % and 26 % (P < 0.05) in FSRT + WBRT and WBRT groups, respectively. The effecting rate was 80 % and 71 % (P 0.05) in FSRT + WBRT and WBRT groups, respectively. The middle survival time was (11.0 ± 1.5) months and (6.5 ± 0.5) months (P < 0.05) in FSRT + WBRT and WBRT groups, respeetivley. The 0.5-, 1.0- and 1.5-years survival rate was 63 % and 41 % (P 0.05), 51 % and 23 % (P 0.05) and 24 % and 9 % (P < 0.05) in FSRT + WBRT and WBRT groups, respectively. Conclusions The method with FSRT plus WBRT in the treatment of brain metastases tumor is safe and relieved focal symptom of patients quickly with lesser injury on normal tissue and the survival time be prolonged, it has better therapeutic effects than WBRT alone for treating brain metastases tumor. 相似文献